219 related articles for article (PubMed ID: 12231370)
41. Mycophenolate mofetil monotherapy in liver transplantation.
Stewart SF; Hudson M; Talbot D; Manas D; Day CP
Lancet; 2001 Feb; 357(9256):609-10. PubMed ID: 11558493
[TBL] [Abstract][Full Text] [Related]
42. Inhibiting the NO pathway with intracoronary L-NAME infusion increases endothelial dysfunction and intimal hyperplasia after heart transplantation.
Perrault LP; Malo O; Bidouard JP; Villeneuve N; Vilaine JP; Vanhoutte PM
J Heart Lung Transplant; 2003 Apr; 22(4):439-51. PubMed ID: 12681422
[TBL] [Abstract][Full Text] [Related]
43. Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients.
Pescovitz MD; Govani M
Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S16-21. PubMed ID: 11583940
[TBL] [Abstract][Full Text] [Related]
44. Similar early complication rate in simultaneous pancreas and kidney recipients on tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus immunosuppressive regimens.
Girman P; Lipar K; Koznarova R; Boucek P; Kriz J; Kocik M; Havrdova T; Adamec M; Saudek F
Transplant Proc; 2010; 42(6):1999-2002. PubMed ID: 20692391
[TBL] [Abstract][Full Text] [Related]
45. Oxidized low density lipoproteins inhibit relaxations of porcine coronary arteries. Role of scavenger receptor and endothelium-derived nitric oxide.
Tanner FC; Noll G; Boulanger CM; Lüscher TF
Circulation; 1991 Jun; 83(6):2012-20. PubMed ID: 2040054
[TBL] [Abstract][Full Text] [Related]
46. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
Favi E; Citterio F; Spagnoletti G; Gargiulo A; Delreno F; Romagnoli J; Castagneto M
Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
[TBL] [Abstract][Full Text] [Related]
47. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results.
Guethoff S; Stroeh K; Grinninger C; Koenig MA; Kleinert EC; Rieger A; Mayr T; von Ziegler F; Reichart B; Hagl C; Schramm R; Kaczmarek I; Meiser BM
J Heart Lung Transplant; 2015 May; 34(5):634-42. PubMed ID: 25701373
[TBL] [Abstract][Full Text] [Related]
48. Benefit of mycophenolate mofetil in patients with cyclosporine A-induced nephropathy after lung transplantation.
Zuckermann A; Birsan T; Thaghavi S; Kupilik N; Deviatko E; Dekan G; Wolner E; Klepetko W
Transplant Proc; 1999; 31(1-2):1160-1. PubMed ID: 10083518
[No Abstract] [Full Text] [Related]
49. Effects of Immunosuppressive Medications on Mitochondrial Function.
Nash A; Samoylova M; Leuthner T; Zhu M; Lin L; Meyer JN; Brennan TV
J Surg Res; 2020 May; 249():50-57. PubMed ID: 31918330
[TBL] [Abstract][Full Text] [Related]
50. Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients.
Roth D; Colona J; Burke GW; Ciancio G; Esquenazi V; Miller J
Transplantation; 1998 Jan; 65(2):248-52. PubMed ID: 9458023
[TBL] [Abstract][Full Text] [Related]
51. Role of endothelin-1 and nitric oxide bioavailability in transplant-related vascular injury: comparative effects of rapamycin and cyclosporine.
Ramzy D; Rao V; Tumiati LC; Xu N; Miriuka S; Delgado D; Ross HJ
Circulation; 2006 Jul; 114(1 Suppl):I214-9. PubMed ID: 16820575
[TBL] [Abstract][Full Text] [Related]
52. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
Spagnoletti G; Citterio F; Favi E; Rossi E; Delreno F; De Santis I; Salerno MP; Gargiulo A; Castagneto M
Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
[TBL] [Abstract][Full Text] [Related]
53. Tacrolimus and mycophenolate mofetil provide effective immunosuppression in rat laryngeal transplantation.
Nelson M; Fritz M; Dan O; Worley S; Strome M
Laryngoscope; 2003 Aug; 113(8):1308-13. PubMed ID: 12897551
[TBL] [Abstract][Full Text] [Related]
54. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
[TBL] [Abstract][Full Text] [Related]
55. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.
Staatz CE; Tett SE
Clin Pharmacokinet; 2007; 46(1):13-58. PubMed ID: 17201457
[TBL] [Abstract][Full Text] [Related]
56. Immunosuppressive drugs in paediatric liver transplantation.
van Mourik ID; Kelly DA
Paediatr Drugs; 2001; 3(1):43-60. PubMed ID: 11220404
[TBL] [Abstract][Full Text] [Related]
57. Primary induction with mycophenolate mofetil and corticosteroids in a liver transplant recipient with hepatorenal syndrome.
Carr RR; Yoshida EM; Chung SW; Partovi N
Ann Pharmacother; 1998 Jan; 32(1):45-8. PubMed ID: 9475819
[TBL] [Abstract][Full Text] [Related]
58. Long-term results of mycophenolate mofetil as part of immunosuppressive induction therapy after liver transplantation.
Langrehr JM; Klupp J; Glanemann M; Junge G; Pfitzmann R; Bahra M; Radtke C; Neumann U; Neuhaus R; Neuhaus P
Clin Transplant; 2006; 20(3):272-83. PubMed ID: 16824141
[TBL] [Abstract][Full Text] [Related]
59. Use of intravenous mycophenolate mofetil for graft-versus-host disease prophylaxis in an allogeneic hematopoietic stem cell transplant recipient with an allergic reaction to cyclosporine and tacrolimus.
Dvorak CC; Callard E; Agarwal R
Bone Marrow Transplant; 2006 Aug; 38(3):253-4. PubMed ID: 16785867
[No Abstract] [Full Text] [Related]
60. Effect of tetrahydrobiopterin on selective endothelial dysfunction of epicardial porcine coronary arteries induced by cardiopulmonary bypass.
Stevens LM; Fortier S; Aubin MC; El-Hamamsy I; Maltais S; Carrier M; Perrault LP
Eur J Cardiothorac Surg; 2006 Sep; 30(3):464-71. PubMed ID: 16884906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
